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ABSTRACT 
The study of blood vessel growth and remodeling is a complex endeavor.    
Hypoxia, the lack of oxygen in a tissue, is known to stimulate angiogenesis (the 
growth of new blood vessels), and have little effect on arteriogenesis (the 
enlargement of existing blood vessels).  However, the role of hypoxia in vessel 
function is unknown, but may be determined using the results and methods 
developed in this experiment. 
 Supplied by the bloodstream, oxygen is required by all cells and tissues to 
remain healthy.  If the bloodstream supplying a certain tissue with blood is 
disrupted, the tissue becomes ischemic, often leading to hypoxia.  Hypoxia is the lack 
of oxygen in living tissue; specifically tissue oxygen levels less than 10 mmHg 
(hypoxyprobe.com). 
 When a tissue is ischemic, and therefore hypoxic, angiogenesis is known to 
occur, which expands the nutrient and waste exchange capacity of the 
microcirculation. Hypoxia-inducible factor (HIF) is a transcriptional regulator of 
angiogenic molecular pathways and is regulated according to the oxygen availability 
in a given tissue (Pugh, Ratcliffe). 
By studying the locality of hypoxia within a given tissue, it is possible to 
predict the behavior of the growing blood vessel.  Additionally, changes in vessel 
function may be understood by comparing the location of hypoxia with the location 
of the altered function.  Cal Poly’s microcirculation laboratory is interested in 
investigating the effects of hypoxia, either prior or sustained, on vascular reactivity.  
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In order to carry out this investigation, a method for assessing the level of hypoxia 
throughout the tissue is needed. 
 In this study, immunohistochmeical staining techniques were used to visually 
map hypoxia in ischemic mouse hindlimb skeletal muscle.  The technique, which 
was developed into a repeatable protocol, may be useful in further investigating 
hypoxia induced vascular growth and changes in function.  
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INTRODUCTION 
 Many physiological processes involve the control of tissue blood flow.  Blood 
flow control mechanisms act to maintain the functionality of blood, including 
transportation of nutrients, regulation of pH levels, and defense against pathogens 
(Marieb).  Because of the wide oxygen demand (due to the wide metabolic range) of 
skeletal muscle, the health of the tissue is critically dependent on acute blood flow 
control.  (Jain).  
 In cases of pathology, blood vessels can become occluded, affecting vascular 
reactivity and blood flow control.  Many things can occlude vessels, disrupting 
normal blood flow.  Atherosclerosis is a condition where the diameter of a blood 
vessel is dramatically lessened due to a build up of fatty substances in the vessel 
lumen (Maton).  Ligation of the vessel prevents blood flow through the pathway to 
some degree.  Occlusion, due to atherosclerosis, ligation, or other causes, lessens or 
eliminates blood flow through a vessel, causing the tissues normally supplied with 
blood from those vessels to be ischemic.  The ligation treatment experimentally 
models ischemic conditions that would be found in response to pathologic arterial 
occlusion, such as atherosclerosis. 
Tissues respond complexly to arterial occlusion.  If the occlusion causes 
injury, inflammation can occur.  Inflammation and hypoxia together may cause 
myofiber death and regeneration, in which muscle fibers re-grow to repair the 
damage that caused inflammation in the first place (Marieb).  In addition to these 
possibilities, injury or any other disruption to the flowing capacity of blood vessels 
has two main results.  First, arterial occlusion increases angiogenesis, the growth of 
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new vessels from existing vessels, and may increase arteriogenesis, and the outward 
remodeling of existing collateral vessels.  These changes in microvascular 
architecture help maintain sufficient oxygen delivery.  Secondly, occlusion decreases 
vessel wall function, in terms of the ability of the vessel to constrict or dilate 
(Marieb).  When vessel wall function is impaired, specifically by injury, the vessel 
has less control over blood flow, thereby decreasing the microvascular function of 
the vessel, and the health of the affected tissue.  
Because vessel injury usually leads to ischemia, which tends to cause 
hypoxia, hypoxia can be viewed as the catalyst for increased angiogenesis, and 
decreased vessel wall function.  The goal of Cal Poly’s Microcirculation and Tissue 
Repair lab is to investigate how changes in vessel architecture, in terms of 
angiogenesis, usually catalyzed by injury, affect blood flow, and why vessel injury 
affects vessel wall function. 
A common consequence of ischemia is hypoxia, where a tissue is deprived of 
a certain level of oxygen (Marieb).  Hypoxia, as a consistent consequence to blood 
vessel injury, affects angiogenesis and perhaps vessel wall function.  However, the 
exact impact of hypoxia on vessel wall function is unknown.  In order to understand 
how hypoxia affects vessel wall function, the physical location of hypoxia needs to 
be correlated to the physical locations of dysfunctional resistance vessels.  This 
correlation may reveal more specifically how hypoxia impacts vascular reactivity.  
The focus of this study is to determine the geographical behavior of hypoxia in 
ischemic tissues of the mouse hindlimb, which can further be used to understand 
how hypoxia impacts vascular reactivity. 
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METHODS 
Overview 
 
 The purpose of this study was to develop a protocol for hypoxia mapping in 
ischemic mouse hindlimb skeletal muscle that the microcirculation lab could use in 
the future to examine the correlation between hypoxia and vascular function.   
In this study, mice were used to map hypoxia in the calf muscle under 
ischemic conditions.  Pimonidazole was injected into the anesthetized mouse.  Next, 
the femoral and saphenous artery-vein pair were resected, such that the hindlimb 
skeletal muscle became ischemic.  The tissues were dissected, fixed in Histochoice, 
processed, and embedded for histological use.  Immunohistochemistry was then 
used to stain cross sections of the ischemic hindlimb tissue for areas of hypoxia. 
 Three surgeries were completed, each of which differed slightly from the 
others, in the attempt to achieve successful hypoxia maps.  As was the staining 
protocol, the injection and surgical protocols were developed during execution.    
Process parameters were modified in the attempt to optimize the protocols. 
 
Injection 
Pimonidazole hydrochloride (Hypoxyprobe) was used as a hypoxia marker.  
Once an intraperitoneal injection into the mouse was made, Hypoxyprobe bound to 
hypoxic cells, or those cells with the partial pressure of oxygen less than 10 mmHg 
at 37 deg C.  However, the pimonidazole required time to diffuse into the 
bloodstream and circulate throughout the body before it was able to even reach all 
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hypoxic cells.  In this sense, the injection timing was critical.  In surgery 1, 25 
minutes were allowed between injection and the first ligation of the resection 
surgery.  For surgery 2, 55 minutes were allowed between injection and initial 
ligation.   For surgery 3, 20 minutes were allowed for uptake and circulation of 
pimonidazole by the blood after injection and before ligation. 
 
Resection 
In the next step of the surgery, the femoral artery-vein pair and saphenous 
artery-vein pair were resected from the left hindlimb, according to the established 
protocol developed by the microcirculation and tissue repair lab.  To do this, the fur, 
skin, connective tissue, and fat pad were removed so that the vasculature was 
exposed on the medial aspect of the hindlimb.  Two ligations were made, one 
between the knee and ankle, and the other just upstream of the muscular branch.  
Once ligated, the vessels between each suture were removed.  This step, from the 
first ligation to the second, took different amounts of time.  For surgery 1, it took 4 
minutes, for surgery 2, it took 25 minutes, and for surgery 3, it took 20 minutes.  The 
right hindlimb in all three surgeries was left untouched, so that ischemic conditions 
were only induced in the left hindlimb skeletal muscle. 
 
Perfusion Fixation 
Perfusion fixation is a step, paired with a vasodilator cocktail, intended to 
dilate, remove the blood from, and fix tissues throughout the entire body.  The 
purpose of fixation is to disable damaging biomolecules, protect the sample from 
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foreign microorganisms, and increase the mechanical strength of the samples to 
maintain the morphology of the tissue.  The benefit of fixation is that it preserves the 
vessels in a natural state, and allows them to be easily analyzed during histology.     
Perfusion fixation is a method of fixation where the fixative is administered 
through the blood stream.  Enough fixative to enter every vessel was administered 
into the heart and allowed to spread through the body.  The tissues remained alive 
until the moment the fixative reached them.  In this way, tissue integrity was 
maintained more than it would be with immersion fixation (where dissected tissues 
are placed in a fixative).  With immersion fixation, no administration of fixative 
occurred through the bloodstream, and the fixative diffused throughout the organ. 
 
Stimulation 
Tungsten microelectrodes were used to stimulate muscle contraction.   
Electrodes were impaled into to the calf muscle and used to deliver current for 90 
seconds at 8 Hz, 0.5 ms, 2 mA.  The resulting muscle contraction required ATP to 
support actin-myosin cross bridge cycling.  Oxygen in the calf skeletal muscle, which 
was used in the production of ATP, was depleted by the induced muscular 
contraction, and could not be restored by the bloodstream because of the resection.  
Therefore, stimulation of skeletal hindlimb muscle after resection of the femoral and 
saphenous artery-vein pair should have quickly depleted the tissue of oxygen, 
leaving it highly hypoxic. 
Following the resection step, the procedure varied greatly between surgeries.  
For surgery 1, another period of waiting was implemented, this time 40 minutes, in 
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order to allow the circulating Hypoxyprobe to bind to newly hypoxic cells.  After this 
period of waiting, a perfusion fixation was implemented, directly followed by tissue 
harvest.  In surgery 2, 35 minutes if wait-time was allowed after resection and 
before tissue dissection, with no perfusion fixation step.  Instead, tissues were fixed 
by immersion directly following dissection.  In surgery 3, stimulation was used in 
the left calf only in an attempt to increase the level of hypoxia in the tissue.  After 
this, 20 minutes of rest were used to allow the Hypoxyprobe to bind to newly 
hypoxic cells before dissection and immersion fixation. 
 
Dissection 
 After either a period of waiting, or in the case of surgery 1, perfusion fixation, 
tissues were dissected from the euthanized animal.  The main tissues of interest for 
the dissection were the calf and the gracilis muscle.  These tissues were dissected 
from the ischemic left, and non-ischemic right hindlimb, and immersed directly into 
fixative.  In surgery 1 and 2, Histochoice was used as a fixative.  In surgery 3, the 
tissue was fixed with formalin.  All three sets of tissues were left immersed in 
fixative for 24 hours before processing.  The general injection protocol, subject to 
the mentioned alterations, is attached in Appendix A.  Below is a summary of the 
differences between surgeries. 
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Table 1. İnjection Factors 
 Surgery 1 Surgery 2 Surgery 3 
Time from injection to resection start 26 min. 57 min. 21 min. 
Time in resection 4 min. 26 min. 19 min. 
Time from resection end to dissection 
start 
40 min. 35 min. 34 min. 
Total time 70 min. 118 min. 74 min. 
Stimulation? No No Yes 
Perfusion/fixation? Yes No Yes 
Fixative Histochoice Histochoice Formalin 
Fixative temperature Room 
temperature 
4 deg C 4 deg C 
 
Processing 
 Sample processing was required before the tissues could be embedded for 
histological purposes.  Processing involved two main steps:  dehydration and 
clearing.  Tissues were placed in labeled cassettes and in an automatic processor.  
The processing was done automatically over night.  Dehydration involved removing 
water from the samples, and consisted of a series of steps where the samples were 
rinsed with increasing concentrations of alcohol.  After dehydration, the tissue 
underwent clearing.  The purpose of clearing is to remove the dehydrating reagents 
from the previous step, usually with xylene.  Additionally, the processor infiltrated 
the tissue with paraffin wax. 
 
Embedding 
 Once the samples were dehydrated and cleared in the automatic processor, 
they were embedded in paraffin wax.  The tissues were cut in half along their cross-
section, placed in hot wax and aligned in a plastic cassette.  The wax was allowed to 
cool and harden into a block ready for sectioning. To map hypoxia in the dissected, 
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ischemic tissues, histological analysis was used.  Eight μm sections of tissue were 
taken with a microtome and placed on microscope slides. 
 
Staining 
 In this study, immunohistochemistry (IHC) was used to stain for hypoxia.   
Pimonidazole, which was injected into the animal before dissection, formed adducts 
when bound to proteins in hypoxic cells, whıch were the antigen source for the IHC 
stain.    Therefore, a series of antibodies specific to pimonidazole-protein adducts 
produced a visual representation of the hypoxic gradient when added to the 
sectioned hypoxic tissues that were injected with pimonidazole. 
 The primary reagents in the immunohistochemical stain were the blocking 
serum, primary antibody, secondary antibody, avaidin-biotin enzyme, and 
peroxidase substrate.  All of these reagents had crucial roles that contributed to the 
resulting stain of hypoxic regions. 
In this study, pimonidazole that was bound to protein in hypoxic 
environments acted as the antigen.  The level of pimonidazole binding was expected 
to increase as the level of hypoxia increased.  Pimonidazole labeled all hypoxic 
tissue by binding proportionately to each one, resulting in darker staining where 
more hypoxia existed.  Non-specific binding of antibodies or enzymes to cells 
without pimonidazole adducts was prevented by the blocking solution. 
The next key factor in the general IHC staining process was the primary 
antibody.  The Hypoxyprobe kit included a mouse immunoglobulin monoclonal 
antibody (MAb IgG1), which detected and binds only to pimonidazole antigens in the 
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tissue.  Next, a biotinylated secondary antibody was introduced to the tissue, which 
bound with the primary antibody.   Biotin, a B-complex vitamin, which was 
conjugated to the secondary antibody, facilitated signal amplification in later steps. 
After the biotinylated secondary antibody had bound to the primary antibody 
(which was bound to the antigen), avidin was added.  Avidin and biotin form strong 
covalent bonds.  In this case, avidin bound to the biotin molecule that was 
conjugated to the secondary antibody, at the hypoxic site.  Finally, biotinylated 
peroxidase was added to the tissue.  Each avidin molecule bound four biotin 
molecules, so for each avidin bound to each biotinylated secondary antibody, there 
were three biotinylated peroxidase molecules that attached to the complex.  This 
mechanism lead to sıgnal amplification, because more peroxidase molecules were 
present than were pimonidazole adducts.  The peroxidase developed an added 
reagent, diaminobenzidne (DAB), into a brownish precipitate.  When DAB was 
added, it should only turn brown in the presence of peroxidase.  In this way, the 
more hypoxic the cell was, the darker brown it appeared.  The results of the process 
were stained tissues on microscope slides, appearing in shades of brown.  If 
successful, the degree of shading throughout each tissue cross-section correlated to 
the amount of hypoxia present there at the time of harvest. 
In this study, an ABC kit from Santa Cruz Biotechnology was used (ABC-
2017).  The kit provided most of the undiluted reagents, such as blocking serum 
stock, secondary antibody stock, avadin, biotinylated horse radish peroxidase, 
substrate buffer, DAB chromagen, and peroxidase substrate.  These reagents were 
combined into steps and diluted in PBS or deionized water.  For example, blocking 
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serum stock and secondary antibody stock were provided components but were 
separately diluted in PBS.  The following are the consolidated IHC steps provided by 
the ABC kit:  blocking solution, secondary antibody, avidin-biotin enzyme, and 
peroxidase substrate.  Hypoxyprobe provided the primary antibody. 
Just as the vague injection protocol provided by the Hypoxyprobe 
manufacturer was interpreted several times to fit the needs of this study, so was the 
existing IHC protocol.  Originally, the Immunohistochemistry protocol was used for 
staining alpha smooth muscle actin, with the ABC kit.  The steps were altered before 
and during trials to mold the protocol into one that produced successful hypoxia 
maps.  Several of the main alterations are as follows:  lessening time in dehydration 
steps, and changing the primary antibody (depending on the antigen stained for).  
The most updated version of the staining protocol can be viewed in Appendix B.  
Another IHC staining protocol, provided by Hypoxyprobe, was interpreted and used 
for one run in this study (Appendix C).  However, the modified alpha smooth muscle 
actin protocol (Appendix B) was used for most runs, because the technique was 
more straight forward, and the protocol had already produced successful results 
with the smooth muscle actin antibody. 
In this study, two different experimental conditions were implemented, so 
that four different groups existed for each trial.  The only group that should have 
had positive staining was the ischemic primary group.  This is because pimonidazole 
IHC peroxidase staining only stains for hypoxia, which should only be present in 
significant quantities in the ischemic tissue.  Moreover, the success of the whole IHC 
process depended on the presence of the primary antibody.  Without the primary 
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antibody, the rest of the reagents (secondary antibody, avidin, biotin, peroxidase, 
and DAB) would not bind to or be developed near hypoxic cells, thereby failing to 
create a dark shade and more importantly, a hypoxia map.  Therefore, hypoxic 
staining was only expected in ischemic tissues treated with primary antibody.  The 
conditions and groups used in this study are summarized below: 
Table 2. Experimental Setup 
 Ischemic Tissue Non-ischemic Tissue 
Primary Antibody Ischemic, Primary Group 
(expected positive 
results) 
Non-ischemic, Primary Group 
No Primary Antibody Ischemic, Control Group Non-ischemic, Control Group 
 
Repetition is a useful way of increasing the percentage of success in scientific 
processes.  Although some factors were changed between runs, many factors 
remained unchanged.  Repeated processes became more robust because of the need 
for the scientist to improve their technique. The repetition of the technique did 
seem to yield better results; proportional to the number of times the process was 
performed. 
 
RESULTS 
 Some success was achieved from the modified alpha smooth muscle actin 
IHC staining protocol.  As listed in the table below, several staining outcomes were 
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possible.  Often, either the sectioning process or staining itself lead to too much 
tissue loss to decipher the results of the stain.   This issue was addressed in different 
ways throughout the trials.  For example, less time was spent in the dehydration 
steps, and an air-dry step was added into the beginning of the stain.  Also, sections 
were more carefully chosen, so that the tissue started out with more integrity.  
Additionally, extra care was taken when moving the slides vertically into or out of 
reagents.  The best procedure for maintaining tissue integrity has been included in 
the optimized staining protocol (Appendix B). 
 Another common result of this study was “no distinction” between the 
control and experimental groups.  In other words, the tissues on the slides looked 
about the same in shade and shade pattern, regardless of the presence or absence of 
the primary antibody.  These results are poor because, as described  previously, the 
chromagen should only have been developed where primary antibody had attached.  
When the same brown coloring occurred in groups that were treated with primary 
antibody and those that weren’t, the validity of the results in the experimental group 
were questionable.  That is, the brown shaded hypoxia maps obtained from tissues 
treated with primary were probably not accurate, because the same hypoxia maps 
were produced without the primary antibody.  This suggested that non-specific 
binding, or some factor other than hypoxia and the primary antibody, was playing a 
role in staining the tissue, which lead to false positives and incorrect maps. 
On the other hand, “no distinction” could also indicate false negative staining.  
It was actually difficult to tell whether false positive or false negative staining had 
occurred if ischemic control and ischemic primary tissues stained the same, because 
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this study is based on relative shading (between primary and control groups).  
Either way, if both the primary and control ischemic tissues came out the same, the 
results were not accurate.  In the results table, below, this outcome is simply named, 
“no distinction”.  Another form of “no distinction” was where, within primary 
antibody treated groups, there was no difference in shading of tissue between 
ischemic and non-ischemic tissues.  This result probably did not reflect reality 
because tissues that underwent induced ischemia should certainly have been more 
hypoxic than tissues that did not.  However, this distinction was absent in some 
results.    This disconnect indicated that either the ischemic tissues were not stained 
in a way that properly represented their hypoxia, or that non-ischemic tissues were 
stained such that more hypoxia was represented than actually existed.  Either way, 
the results were not reliable. 
 The more successful results are denoted in the results table as “distinction in 
one slide”, “distinction in two slides”, or “distinction in some slides”.  In these cases, 
there were expected differences in shading between control groups and 
experimental groups.  Again, positive staining was only expected in one of four 
scenarios:  the tissue was ischemic and treated with primary antibody.  When there 
was clearly more shading (either in area or depth) in tissues that met this criteria 
than tissues either without ischemia or without primary antibody, the stain was 
successful.  Never were the results clear across all slides in the run (usually about 
eight slides total).  As stated in the staining results table below, distinction either 
occurred in one slide or some slides, but never in all slides.   Modification of the 
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injection and staining protocol and repetition of both techniques could increase the 
percentage of success (from about 15% now). 
Below is a summary of each stain and its results.  The results for stain 2 that 
read, “non-ischemic distinctions” refer to the specific issue of false positive staining 
in tissue that should not have great amounts of hypoxia, because the vessel in the 
hindlimb from which the tissue was not resected, and thus, ischemia was not 
induced. 
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 Table 3. Staining Results 
 Surgery Tissue Protocol Oven setting Results 
Stain 1 1 Calf Appendix C 7 No Distinction. 
Stain 2 1 Calf Appendix B 7 Distinction in some slides. 
Non-ischemic distinctions. 
Stain 3a 1 Calf Appendix B 7 Distinction in one slide. 
Stain 3b 2 Calf Appendix B 7 No Distinction. 
Stain 4a 2 Calf Appendix B 7 Too much tissue loss. 
Stain 4b 3 Calf Appendix B 7 Too much tissue loss. 
Stain 5a 2 Calf Appendix B 7 Too much tissue loss. 
Stain 5b 3 Calf Appendix B 7 Too much tissue loss. 
Stain 6 3 Calf Appendix B 7 Distinction in two slides. 
Stain 7a 2 Calf Appendix B 7 Distinction in some slides. 
Stain 7b 3 Gracilis Appendix B 7 No distinction. 
Stain 7c 3 Calf Appendix B 7 Distinction in some slides. 
Stain 8a 2 Calf Appendix B 3 Distinction in one slide. 
Stain 8b 3 Calf Appendix B 3 No distinction. 
Note:  Oven setting refers to the oven in Bonderson room 209.  Setting 7 correlates 
to over 100 °C, whereas setting usually results in 30-40 deg C. 
 
 The results listed in the table above were observed visually using a white-
light microscope. The photomicrographs below show pairs of slides representing 
various outcomes.  Only the same tissue was compared between control and 
experimental treatments, because the skeletal muscle architecture was so different 
from tissue to tissue.  No adjustments to the lighting, white balance, or zoom were 
made on the microscope between the primary and control of each pair of photos.  
Thus, if there was a difference in appearance between a pair of the same tissue, it 
was due to the stain. 
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Successful Stains 
 
 
Figure 1 shows successful results in non
no difference in shading between the control and primary 
in the whole tissue.  This was expected because the tissue was 
non-ischemic, and should not have been hypoxic.  Therefore, both 
control and primary groups should be about equally unshaded.
Figure 1a.  Control 
 
Figure 1b.  Primary 
-ischemic tissue.  There is 
groups 
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Figure 2 also shows successful results in non
seen in the zoomed image, there is very little difference in 
contrast between the control and primary groups, as expected for 
non-hypoxic tissue.
Figure 2a.  Control 
Figure 2b.  Primary 
 
-ischemic tissue.  As 
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Figure 3 shows successful results in ischemic tissue.  There is an 
obvious difference in overall shading between control and 
primary groups, correctly representing hypoxia in the primary 
group, as stained for using 
regional, but rather, evenly spread through all tissue areas of the 
experimental group.  Although the tissue in figure 3a and 3b is the 
same, and should have similar hypoxia levels in its sections, 
hypoxia shouldn’t 
primary antibody.
Figure 3a.  Control 
 
Figure 3b.  Primary 
IHC.  This shading seems not to be 
be depicted unless the tissue was treated with 
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Figure 4 features the same 
figure 4’s image is magnified.  Again, it is clear that the tissue 
treated with primary antibody is generally darker than the 
control.  Additionally, the increased contrast seems to be located 
evenly throughout the experimental tissue, not just in certain 
areas. 
Figure 4a.  Control 
 
Figure 4b.  Primary 
 
tissue sample as figure 3, however 
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Figure 5 shows a more localized form of success in an ischemic 
tissue.  Here, the ti
staining as compared to the control tissue in individual cells 
rather than in overall shade.  This localized response may be 
closer to the expected hypoxic response of the tissue to ischemia.  
It is possible that ischemia does cause a locally variable hypoxic 
response. 
Figure 5a.  Control 
 
Figure 5b.  Primary 
ssue treated with primary antibody shows dark 
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Unsuccessful Stains 
 
Figure 6 shows no distinction between control and primary 
groups in an ischemic tissue.  Becaus
brown staining was expected for the primary group only, thereby 
creating a difference in staining between control and primary 
groups.  The dark brown areas seen in the primary group are 
simply the result of tissue folding, not successful staining.
Therefore, this stain was unsuccessful.
 
Figure 6a.  Control 
 
Figure 6b.  Primary 
e the tissue is ischemic, dark
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Figure 7 shows a magnified view of the 
Again, this slide was unsuccessful because, unexpectedly, there is 
very little difference in shading between cont
groups.  Because there is no difference between groups, it cannot 
be determined whether false positive or false negative staining 
has occurred. 
Figure 7a.  Control 
 
Figure 7b.  Primary 
tissue from figure 6.  
rol and primary 
 
 
25 
Figure 8 shows another unsuccessful stain in an ischemic tissue.  
Again, as seen from the image of the whole calf cross
there is very little difference in contrast between the control and 
primary treated tissue, even though the tissue is expected to be 
hypoxic.  In fact, there seems to be slightly more staining in the 
control tissue than in the primary, which is opposite of the 
expected hypoxic reaction in these two tissues.
unsuccessful because the primary treated tissue is not shaded 
more than the control tissue.
 
Figure 8a.  Control 
 
 
Figure 8b.  Primary 
 
-section, 
  The stain was 
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Figure 9 shows a magnified view of the ischemic tissue from figure 
8.  Here, it is clear that the control group’s shading is slightly more 
defined than is the experimental group’s.  
group may be falsely positive and the primary group may be 
falsely negative. 
Figure 9a.  Control 
 
Figure 9b.  Primary 
In this case, the control 
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Figure 10 shows more contrast in the primary tissue than in the 
control tissue.  This result would be expect
ischemic, but the tissue is non
hypoxia is expected, and therefore there would be little staining, 
regardless of whether the sample was treated with primary 
antibody or not.  This result is unsucces
displaying the location of hypoxia.
Figure 10a.  Control 
 
Figure 10b.  Primary 
ed had the tissue been 
-ischemic.  Because of this, little 
sful at accurately 
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Figure 11 displays a magnified view of the tissue in figure 10.  
Although it is slight, the shading in the experimental group may 
be more defined than the shading in the control group.  Again, this 
stain is unsuccessful.  Both groups are expected to have little to 
shading due to the lack of ischemia in the tissue.
 
Figure 11a.  Control 
 
Figure 11b.  Primary 
 
 
 
 
no 
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Figure 12 shows a sample that has had too much tissue loss for 
staining analysis. 
 
 
 
Figure 12. 
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DISCUSSION 
There were some successful results of this study, supporting the proof-of-
concept for mapping hypoxia in mouse hindlimb skeletal muscle.  Although there 
were some false positives in every batch, the validity of the successful slides is not 
undermined.  However, instead of using successful slides as definitive victories, they 
must be looked at as possibilities of future success.  Although it can’t be told if the 
successful-looking slides represent accurate maps of hypoxia in the tissue used, the 
more frequently these successful results occur, the more likely this is the case. 
There were also unsuccessful slides.  In general, “no distinction where there 
should have been”, and “distinction where there should not have been” were the two 
incorrect outcomes that occurred.  These false positives or false negatives indicate 
either over-staining of non-hypoxic cells or under-staining of hypoxic cells.  The 
incorrect stains could be the result of mistakes in technique or logic in injection, 
surgery, processing and embedding, sectioning, or staining. 
 The lack of staining where there should be (false negative) or the presence of 
staining where there should not have been (false positive) are both logical 
possibilities for results that have no distinction in tissue shading between control 
and experimental groups.  However, it is difficult to distinguish which scenario has 
played out, because success was measured in this study by comparison between 
samples.  Therefore, if there was no distinction between an ischemic control tissue 
and an ischemic experimental tissue, it was deducible that the run was unsuccessful, 
but it was hard to discern more than that.  Postulations have been made, however, 
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as to what has caused some of the poor results.  No distinction would be apparent 
where expected if the surgery did not cause significant hypoxia.  Many things could 
go wrong with the injection, resection, and dissection technique and timeline, 
resulting in an unnoticeable change in hypoxia levels.  In this case, the negative 
would not be false, but unexpected.  Moreover, because the blocking serum bound to 
and blocked open binding sites, if the tissue was treated with blocking serum out of 
sequence, false positive staining would have occurred.  Finally, underexposure to 
DAB is a condition that could possibly lead to false negatives.  DAB needed time to 
develop into a brown hue, and if this time was not allowed, little or no staining may 
have been seen.  On the other hand, false positive results may have been caused by 
non-specific binding of antibodies.  The technique of immunohistochemistry 
depends on specificity between antigens and antibodies.  For example, if the binding 
of primary antibody was not specific to pimonidazole, not only hypoxic cells would 
be stained.  Additionally, false positive staining could be caused by over-exposure to 
DAB.  Because both false positive and false negative staining occurred in most trials, 
a combination of the issues mentioned probably occurred. 
 More successful slides per run and the limitation of false positive and false 
negative slides are desirable goals.  To do this, there are many avenues for protocol 
modifications.  It is the hope that one or a combination of some of the following 
suggestions may help to increase the ratio of good slides to bad slides.  The 
suggestions for the future are as follows: 
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Table 4.  Future Suggestions 
Alter the surgery timing to allow for better circulation of pimonidazole, more 
hypoxia, or better binding of pimonidazole to hypoxic cells 
Alter the exposure time of the samples to the DAB chromagen 
Use the staining protocol provided by Hypoxyprobe (Appendix C) 
Keep the oven setting as low as 3 or 4 (so as not to damage the tissue) 
Use other hindlimb tissues 
Use more repetition and larger sample sizes to override technique problems 
 
 
The successes achieved in this study have validated, in part, the developed 
protocol for hypoxia mapping in ischemic mouse hindlimb skeletal muscle.  It is true 
that the protocol, which produces consistent true positive results, needs to be 
further developed, but that protocol could be largely based on the one used in this 
study.  Much has been discovered about the nature of immunohistochemical 
staining in hypoxic mouse tissue, and these discoveries can be used to further 
perfect the hypoxia mapping technique. 
The developed injection and staining technique can be used by the 
microcirculation lab to asses the presence of hypoxia near the muscular branch 
artery. Vascular reactivity measurements have already been, and continue to be, 
collected from this area, so adding the developed procedure for hypoxia mapping 
may help draw connections between regional oxygen levels and vascular function. 
Hypoxia's role in vasuclar reactivity, whether it be in vessel growth, or in vessel wall 
functionality, may be established with this or subsequent modifications of this 
protocol. 
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APPENDIX 
Appendix A:  Injection Protocol 
 
Injection Protocol 
Interpreted by Emily Deckert, August, 2010 
 
This protocol can be altered to achieve better results.  What is written has not yet 
been verified to be the best injection method.  Things to alter include timing, 
fixatives, and temperatures.  Additionally, after the injection and staining protocol 
have been optimized for use in the lab as a method to map hypoxia, this injection 
protocol can be altered to work in conjunction with other studies involving the 
animal. 
 
• Timing:   
o Injection 
o Resection 
o Stimulation 
o Dissection 
o Fixation 
• Injection: 
o Intraperitoneal 
o Solution: 250 µL PBS, 1.8 mg pimonidazole per mouse 
o Hypoxyprobe injection at room temp, store in fridge, but do not 
freeze. 
• Resection: 
o Following current lab protocol 
o Only resect one limb.  The other will serve as a control. 
• Stimulation: 
o Optional 
o Using the lab’s electrodes, stimulate the calf for 90 seconds:  8 Hz, 0.5 
ms, 2 mA 
• Dissection: 
o 15 to 90 minutes (or 1-2 hours) after injection (Hypoxyprobe will be 
“frozen” in place at the time of harvest). 
o Actual harvest time as quick as possible. 
• Fixation: 
o Immersion fixation in formalin 
o Let sit in fixative over night at room temp 
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Appendix B:  Staining Protocol 
 
Immunohistochemcial Hypoxia Staining Protocol 
Emily Deckert, August 2010 
Adapted from protocols from Chris Miracle and Santa Cruz Biotechnology 
 
1. Incubate slides for 5 – 10 minutes in oven after sectioning 
a. Prepare blocking serum.  Mix in blue bottle. 
i. 75 µL normal goat blocking serum stock 
ii. 5 mL PBS  
2. Dip with Xylene – 10 min 
3. Air dry – 30 sec 
4. Dip with 100% ethanol – 2 min 
5. Air dry – 30 sec 
6. Dip with 95% ethanol – 1 min 
7. Incubate slides (room temperature) with blocking serum – 1 hour* 
a. Prepare primary antibody 30 – 45 minutes into step 7.  Mix in 
disposable centrifuge tube. 
i. Pipette 30 µL Hypoxyprobe İgG mouse monoclonal antibody 
(with an antibody solution concentration of 70 µg/mL) 
ii. Pipette 970 µL blocking serum 
(The resulting antibody solution concentration is 2 µg/mL) 
b. Suction reagent (blocking serum) after 1 hour** 
i. Suction 1 slide at a time, proceed to step 8 and repeat for each 
slide 
8. Incubate slides (room temperature) with primary antibody – 30 min 
9. Wash with 3 changes of PBS – 5 min each 
a. During these washes, prepare secondary antibody.  Mix in green 
bottle. 
i. 75 µL normal blocking serum stock 
ii. 5 mL PBS 
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iii. 25 µL secondary antibody stock 
10. Incubate slides (room temperature) with secondary antibody solution – 
30 min 
a. During this step, prepare AB enzyme reagent.  Mix in purple bottle. 
i. 50 µL avidin 
ii. 50 µL biotinylated horse radish peroxidase (HRP) 
iii. 2.5 mL PBS 
11. Wash with 3 changes of PBS – 5 min each 
12. Incubate slides (room temperature) with AB enzyme (having allowed 
the AB enzyme to sit for 30 minutes)– 30 min  
13. Wash with 3 changes of PBS – 5 min each 
a. During these washes, prepare peroxidase substrate.  Mix in yellow 
bottle. 
i. 1.6 mL distilled water 
ii. 5 drops 10X substrate buffer 
iii. 1 drop 50X DAB chromogen 
iv. 1 drop 50X peroxidase substrate 
14. Incubate with peroxidase substrate – 5 min 
15. Wash in distilled water – 4 min 
16. 95% ethanol – 10 sec 
17. 100% ethanol – 10 sec 
18. Xylene  - 25 sec 
19. Coverslip each slide individually and prior directly from xylene 
 
*Note: Use a food container dish with a moist paper towel on the bottom to 
create a moist chamber environment for incubating both inside and outside 
of the hood for all incubation steps. 
**Note: Use suction pump/vacuum to remove reagents one at a time between 
all incubation steps 
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Appendix C:  Alternate Staining Protocol 
 
Immunohistochemical Hypoxia Staining Protocol (Alternate) 
Interpreted by Emily Deckert, August, 2010 
Provided by Hypoxyprobe İnc. 
 
1. Warm paraffinized tissue section.  40°C, 20 min. 
2. Dip and blot 10 times (slides held vertically):  xylene, 2 min. 
3. Dip and blot 10 times (slides held vertically):  100% ethanol, 2 min. 
4. Dip and blot 10 times (slides held vertically):  95% aqueous ethanol, 2 min. 
5. Dip and blot 10 times (slides held vertically):  80% aqueous ethanol, 2 min. 
6. Dip and blot 10 times (slides held vertically):  D.İ. H20 + 0.2% Brij 35, 2 min. 
7. Dip and blot 10 times (slides held vertically):  PBS + 0.2% Brij 35, 2 min. 
8. Incubate (slides held vertically): 3% H2O2 in distilled water, 5 min. 
9. Choose 1, 2, or 3: 
 
1) “Heat treatment (recommended method): Place slides in a container and cover with 10 
mM sodium citrate buffer, pH 6.0; or with 50 mMglycine-HCl buffer (glycine: sc-
29096), pH 3.5, with 0.01% (w/v) EDTA (EDTA: sc-29092). Heat at 95º C for 5 
minutes. Top off with fresh buffer and heat at 95º C for 5 minutes (optimal incubation 
time may vary for each tissue type). Allow slides to cool in the buffer for 
approximately 20 minutes. Wash in deionized H2O three times for 2 minutes each. 
Aspirate excess liquid from slides.” 
2) “Pepsin: Incubate sections for 10–20 minutes in 0.1% pepsin in 0.01 N HCl at room 
temperature. Wash slides several times in deionized H2O. Aspirate excess liquid from 
slides.” 
3) “Saponin: Incubate sections for 30 minutes in 0.05% saponin in deionized H2O at room 
temperature. Wash at least three times in PBS. Aspirate excess liquid from slides.” 
(Santa Cruz Biotechnology, 2010) 
 
10.  Wash:  PBS + 0.2% Brij 35, 0°C, 2 min.  Reagent magnetically stirred in a 
Coplin jar held on ice. 
11.  İncubate (slides held horizontally): Blocking solution, 5 min. (ABC Kit) 
12.  İncubate (slides held horizontally): 1/50 Primary Antibody (for 
Hypoxyprobe, see reagent directions), 40 min. 
13.  Wash (slides held horizontally):  PBS + 0.2% Brij 35, 0°C, 2 min.  Reagent 
magnetically stirred in a Coplin jar held on ice. 
14. Incubate(slides held horizontally): 1/500 secondary antibody in 10 mM PBS, 
with 0.2% Brij 35 and 1 drop protein blocker /mL, 10 min. (ABC Kit) 
15.  Wash (slides held horizontally):  PBS + 0.2% Brij 35, 0°C, 2 min.  Reagent 
magnetically stirred in a Coplin jar held on ice. 
16.  Incubate (slides held horizontally):  Peroxidase substrate, 10 min. (ABC Kit) 
17.  Wash (slides held horizontally):  PBS + 0.2% Brij 35, 0°C, 2 min.  Reagent 
magnetically stirred in a Coplin jar held on ice.  
18. Incubate (slides held horizontally):  Peroxidase chromagen (DAB), 10 min. 
(ABC Kit) 
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19. Wash (slides held horizontally):  distilled H20, 2 min.  Reagent magnetically 
stirred in a Coplin jar. 
20. Incubate: Hematoxylin, 30 seconds. 
21. Wash (slides held horizontally):  distilled H20, 2 min.  Reagent magnetically 
stirred in a Coplin jar. 
22. Crystal/Mount, 20 min. 
(Hypoxyprobe, 2010) 
 
Purposes: 
• 2-7:  depariffinization, hydration 
• 8:  quench tissue peroxidase 
• 9: antigen retrieval 
• 11:  Block non-specific binding 
• 16, 18:  color 
• 20: counterstain 
• 22: mount and dry slides 
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Appendix D:  Staining Log 
 
Blocks denoted by an “(i)” contain ischemic tissues. 
 Date Blocks Surgery Tissue Photo 
Stain 1 7-13-10 10-210  
10-211 (i) 
1 Calf none 
Stain 2 7-16-10 10-210 
10-211 (i) 
1 Calf Figure 1 (210 A) 
Figure 5 (211 A) 
Figure 10 (210 C) 
Figure 11 (210 C) 
Stain 3a 7-17-10 10-210 
10-211 (i) 
1 Calf Figure 2 (210 B) 
Figure 3 (211 C) 
Figure 4 (211 C) 
Stain 3b 7-17-10 10-222 
10-223 (i) 
2 Calf none 
Stain 4a 7-24-10 10-222 
10-223 (i) 
2 Calf Figure 12 (223 D) 
Stain 4b 7-24-10 10-235 
10-236 (i) 
3 Calf none 
Stain 5a 7-25-10 10-222 
10-223 (i) 
2 Calf none 
Stain 5b 7-25-10 10-235 
10-236 (i) 
3 Calf none 
Stain 6 7-26-10 10-235 
10-236 (i) 
3 Calf none 
Stain 7a 7-30-10 10-222 
10-223 (i) 
2 Calf Figure 8 (223 D) 
Figure 9 (223 D) 
Stain 7b 7-30-10 10-233 
10-234 (i) 
3 Gracilis none 
Stain 7c 7-30-10 10-235 
10-236 (i) 
3 Calf none 
Stain 8a 7-31-10 10-222 
10-223 (i) 
2 Calf Figure 6 (223 E) 
Figure 7 (223 E) 
Stain 8b 7-31-10 10-235 
10-236 (i) 
3 Calf none 
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Appendix E:  Hypoxyprobe TM -1 Kit İnformation 
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